We are delighted to announce that Cloyne Pharmacy have been selected as finalists for the QIC Programme Anticoagulation Awards 2014. Cloyne Pharmacy is the first pharmacy in Ireland to run a Warfarin (Anti-coagulation) Clinic in which we take care of patients who take Warfarin and require blood tests on a regular basis.   If you would like more information on our Warfarin Clinic please feel free to contact our team on 021 4652543.

The press release for the awards is shown below.

Finalists announced for QiC Anticoagulation awards programme

The Quality in Care (QiC) partnership is pleased to announced the finalists for its first Anticoagulation awards programme to recognise good healthcare practice in the field of anticoagulation.

Anticoagulation is a therapy field that involves the prevention and treatment of blood clots. It covers a range of serious conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation and endocarditis.

The aim of QiC Anticoagulation is to recognise, reward and share the good practice involved in anticoagulation management, education and patient care. It follows similar successful programmes in diabetes and oncology.

QiC Anticoagulation 2014 features seven finalists across four categories covering key areas of anticoagulation care. Finalists come from healthcare organisations in England, Wales and Ireland and represent a diverse range of projects from NHS, universities and pharmacy.

The full list of finalists

Aneurin Bevan University Health Board and Velindre Cancer Centre
City Hospital, University of Birmingham, and Aston University
Cloyne Pharmacy
East Kent Hospitals University Foundation Trust
Inspira Health Solutions Ltd. and Liverpool Heart and Chest Hospital
Oxford One Stop DVT Diagnostic Clinic
UHBristol

Winners of the 2014 awards will be announced at an event on Tuesday September 30, 2014, at BMA House, Tavistock Square, London.

Judging

The judging group for QiC Anticoagulation 2014 comprised a multi-disciplinary panel of eminent anticoagulation professionals, including nurses, GPs, patient representatives, clinicians, pharmacists, policymakers, and CCG groups.

Judges were chaired by Professor Beverley Hunt, Professor of Thrombosis & Haemostasis, King’s College and Founder and Medical Director of Lifeblood, the Thrombosis Charity, and Eve Knight, Co-Founder and Chief Executive, AntiCoagulation Europe (ACE).

Knight commented: “ACE is proud to support the Quality in Care (QiC) Anticoagulation Programme because it shares our goals of recognising best practice and enabling patients to take a more active role in their own healthcare as well as improving their quality of life.”

Marion McPherson, General Medicine Business Unit Head for QiC Anticoagulation partner Bayer HealthCare commented: “Bayer is delighted to partner the Quality in Care 2014 Anticoagulation programme. Our products and services are designed to benefit people and improve their quality of life which is why we are proud to be associated with a programme that supports the implementation of innovation and good practice in the NHS, resulting in tangible benefits for patients.”

The QiC Anticoagulation Partners

The QiC Anticoagulation Programme is supported by the following organisations:

Bayer HealthCare, AntiCoagulation Europe (ACE)